Literature DB >> 22885775

Synthesis and characterization in monkey of [11C]SP203 as a radioligand for imaging brain metabotropic glutamate 5 receptors.

Fabrice G Siméon1, Jeih-San Liow, Yi Zhang, Jinsoo Hong, Robert L Gladding, Sami S Zoghbi, Robert B Innis, Victor W Pike.   

Abstract

PURPOSE: [(18)F]SP203 (3-fluoro-5-(2-(2-([(18)F]fluoromethyl)-thiazol-4-yl)ethynyl)benzonitrile) is an effective high-affinity and selective radioligand for imaging metabotropic 5 receptors (mGluR5) in human brain with PET. To provide a radioligand that may be used for more than one scanning session in the same subject in a single day, we set out to label SP203 with shorter-lived (11)C (t (1/2) = 20.4 min) and to characterize its behavior as a radioligand with PET in the monkey.
METHODS: Iodo and bromo precursors were obtained by cross-coupling 2-fluoromethyl-4-((trimethylsilyl)ethynyl)-1,3-thiazole with 3,5-diiodofluorobenzene and 3,5-dibromofluorobenzene, respectively. Treatment of either precursor with [(11)C]cyanide ion rapidly gave [(11)C]SP203, which was purified with high-performance liquid chromatography. PET was used to measure the uptake of radioactivity in brain regions after injecting [(11)C]SP203 intravenously into rhesus monkeys at baseline and under conditions in which mGluR5 were blocked with 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP). The emergence of radiometabolites in monkey blood in vitro and in vivo was assessed with radio-HPLC. The stability of [(11)C]SP203 in human blood in vitro was also measured.
RESULTS: The iodo precursor gave [(11)C]SP203 in higher radiochemical yield (>98 %) than the bromo precursor (20-52 %). After intravenous administration of [(11)C]SP203 into three rhesus monkeys, radioactivity peaked early in brain (average 12.5 min) with a regional distribution in rank order of expected mGluR5 density. Peak uptake was followed by a steady decline. No radioactivity accumulated in the skull. In monkeys pretreated with MTEP before [(11)C]SP203 administration, radioactivity uptake in brain was again high but then declined more rapidly than in the baseline scan to a common low level. [(11)C]SP203 was unstable in monkey blood in vitro and in vivo, and gave predominantly less lipophilic radiometabolites. By contrast, [(11)C]SP203 was stable in human blood in vitro.
CONCLUSION: [(11)C]SP203 emulates [(18)F]SP203 with regard to providing a sizeable mGluR5-specific signal in monkey brain, and advantageously avoids troublesome accumulation of radioactivity in bone. Although [(11)C]SP203 is unsuitable for mGluR5 quantification in monkey brain, its evaluation as a PET radioligand for studying human brain mGluR5 is nevertheless warranted.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22885775      PMCID: PMC5577640          DOI: 10.1007/s00259-012-2205-x

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  24 in total

1.  Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice.

Authors:  C Chiamulera; M P Epping-Jordan; A Zocchi; C Marcon; C Cottiny; S Tacconi; M Corsi; F Orzi; F Conquet
Journal:  Nat Neurosci       Date:  2001-09       Impact factor: 24.884

2.  In vivo positron emission tomography imaging with [¹¹C]ABP688: binding variability and specificity for the metabotropic glutamate receptor subtype 5 in baboons.

Authors:  Christine DeLorenzo; Matthew S Milak; Kathleen G Brennan; J S Dileep Kumar; J John Mann; Ramin V Parsey
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-01-29       Impact factor: 9.236

3.  Radiodefluorination of 3-fluoro-5-(2-(2-[18F](fluoromethyl)-thiazol-4-yl)ethynyl)benzonitrile ([18F]SP203), a radioligand for imaging brain metabotropic glutamate subtype-5 receptors with positron emission tomography, occurs by glutathionylation in rat brain.

Authors:  H Umesha Shetty; Sami S Zoghbi; Fabrice G Siméon; Jeih-San Liow; Amira K Brown; Pavitra Kannan; Robert B Innis; Victor W Pike
Journal:  J Pharmacol Exp Ther       Date:  2008-09-19       Impact factor: 4.030

4.  Quantification of metabotropic glutamate subtype 5 receptors in the brain by an equilibrium method using 18F-SP203.

Authors:  Yasuyuki Kimura; Fabrice G Siméon; Sami S Zoghbi; Yi Zhang; Jun Hatazawa; Victor W Pike; Robert B Innis; Masahiro Fujita
Journal:  Neuroimage       Date:  2011-10-19       Impact factor: 6.556

5.  Abnormal mGlu 5 receptor/endocannabinoid coupling in mice lacking FMRP and BC1 RNA.

Authors:  Mauro Maccarrone; Silvia Rossi; Monica Bari; Valentina De Chiara; Cinzia Rapino; Alessandra Musella; Giorgio Bernardi; Claudia Bagni; Diego Centonze
Journal:  Neuropsychopharmacology       Date:  2010-03-10       Impact factor: 7.853

Review 6.  The role of group I metabotropic glutamate receptors in schizophrenia.

Authors:  M Pietraszek; J Nagel; A Gravius; D Schäfer; W Danysz
Journal:  Amino Acids       Date:  2006-05-15       Impact factor: 3.520

7.  Human PET studies of metabotropic glutamate receptor subtype 5 with 11C-ABP688.

Authors:  Simon M Ametamey; Valerie Treyer; Johannes Streffer; Matthias T Wyss; Mark Schmidt; Milen Blagoev; Samuel Hintermann; Yves Auberson; Fabrizio Gasparini; Uta C Fischer; Alfred Buck
Journal:  J Nucl Med       Date:  2007-02       Impact factor: 10.057

8.  On quantitative relationships between drug-like compound lipophilicity and plasma free fraction in monkey and human.

Authors:  Sami S Zoghbi; Kacey B Anderson; Kimberly J Jenko; David A Luckenbaugh; Robert B Innis; Victor W Pike
Journal:  J Pharm Sci       Date:  2011-12-13       Impact factor: 3.534

9.  Noninvasive and quantitative assessment of the function of multidrug resistance-associated protein 1 in the living brain.

Authors:  Toshimitsu Okamura; Tatsuya Kikuchi; Maki Okada; Chie Toramatsu; Kiyoshi Fukushi; Makoto Takei; Toshiaki Irie
Journal:  J Cereb Blood Flow Metab       Date:  2008-11-05       Impact factor: 6.200

10.  Metabotropic glutamate subtype 5 receptors are quantified in the human brain with a novel radioligand for PET.

Authors:  Amira K Brown; Yasuyuki Kimura; Sami S Zoghbi; Fabrice G Siméon; Jeih-San Liow; William C Kreisl; Andrew Taku; Masahiro Fujita; Victor W Pike; Robert B Innis
Journal:  J Nucl Med       Date:  2008-12       Impact factor: 10.057

View more
  5 in total

Review 1.  Considerations in the Development of Reversibly Binding PET Radioligands for Brain Imaging.

Authors:  Victor W Pike
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

Review 2.  Radiolabeling with [11C]HCN for Positron emission tomography.

Authors:  Yu-Peng Zhou; Katarina J Makaravage; Pedro Brugarolas
Journal:  Nucl Med Biol       Date:  2021-09-25       Impact factor: 2.408

Review 3.  Metabotropic glutamate receptor 5 - a promising target in drug development and neuroimaging.

Authors:  Rajapillai L I Pillai; Dnyanesh N Tipre
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-01-07       Impact factor: 9.236

4.  Comparison of two PET radioligands, [11C]FPEB and [11C]SP203, for quantification of metabotropic glutamate receptor 5 in human brain.

Authors:  Talakad G Lohith; Tetsuya Tsujikawa; Fabrice G Siméon; Mattia Veronese; Sami S Zoghbi; Chul Hyoung Lyoo; Yasuyuki Kimura; Cheryl L Morse; Victor W Pike; Masahiro Fujita; Robert B Innis
Journal:  J Cereb Blood Flow Metab       Date:  2016-01-01       Impact factor: 6.200

5.  Synthesis, Biodistribution, and Radiation Dosimetry of a Novel mGluR5 Radioligand: 18F-AZD9272.

Authors:  Sangram Nag; Katarina Varnäs; Ryosuke Arakawa; Mahabuba Jahan; Magnus Schou; Lars Farde; Christer Halldin
Journal:  ACS Chem Neurosci       Date:  2020-03-24       Impact factor: 4.418

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.